TSPO modulation for Alzheimer's disease
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests a drug that targets a brain protein called TSPO in people with mild to moderate Alzheimer's. It aims to see if this approach can slow memory loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 60 and 90 years old
- Have a diagnosis of mild to moderate Alzheimer's disease (MMSE score between 20 and 27)
- Have a specific genetic type (AA at rs6971) for the TSPO protein
- Not have certain liver or kidney problems, or take specific medications that interact with the study drug
- Not have migraines more than once a month or other conditions like sleep behavior disorder
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental treatment called VY1706 for people with early Alzheimer's disease. It aims to see if the treatment is safe and how well it works, and may help slow down the disease.
This study tests a drug that targets a protein called TSPO to see if it can improve the function of the cells lining the small blood vessels in the brain of people with cerebral small vessel disease. It may help with mild memory or thinking problems.
This study tests whether a medicine that targets a specific brain inflammation marker (TSPO) can help in people with certain types of multiple sclerosis. It focuses on safety and whether the target can be measured and influenced during treatment.
This trial tests a new radioactive imaging agent that targets a protein (TSPO) in the brain, which is linked to inflammation. The goal is to see if it can help visualize brain inflammation in people with Alzheimer's disease, potentially aiding in diagnosis and monitoring.
This study uses a special PET brain scan to look at two types of brain immune cells in people with Alzheimer’s. It may help researchers better understand Alzheimer’s and how these cells change over time.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.